Among them, we identified KEAP1 and FBXW7, the loss of which have previously been shown to confer resistance to EGFR TKI treatment in EGFR-mutant NSCLC cells (Krall et al., 2017; Ye et al., 2017). Here, EGFR is linked to non-small cell lung carcinoma.